Edgar Filing: Bolgiano Elizabeth Scott - Form 4

Bolgiano Eli Form 4	zabeth Scott										
February 27,	, 2019										
FORM	14			GEGUD						r	PPROVAL
	UNI	TED S	TATES		ITIES A hington,			NGE (COMMISSION	OMB Number:	3235-0287
bee instruction				Section 16	SECUR 6(a) of the ility Hold	Expires: January 31 2005 Estimated average burden hours per response 0.5					
1(b). (Print or Type I	Responses)										
(Time of Type I	(tesponses)										
1. Name and Address of Reporting Person <u>*</u> Bolgiano Elizabeth Scott			2. Issuer Name and Ticker or Trading Symbol AMAG PHARMACEUTICALS					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(-))				INC. [A]	_						
(Last) C/O AMAC PHARMAC WINTER S	CEUTICALS	,	iddle) ., 1100	3. Date of (Month/Da 02/25/20		insaction			Director X Officer (give below) Chief Hun		6 Owner er (specify Officer
				ndment, Dat th/Day/Year)	-			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
WALTHAN	M, MA 0245	1							Person	Nore than One Ro	eporting
(City)	(State)	(2	Zip)	Table	e I - Non-Do	erivative S	Securi	ties Ac	quired, Disposed o	f, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date 2A. D (Month/Day/Year) Exect any (Mon		Execution any		3.4. SecuritiesTransactionAcquired (A) orCodeDisposed of (D)(Instr. 8)(Instr. 3, 4 and 5)		SecuritiesHBeneficially(OwnedH	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common					Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	02/25/201	9			А	7,500 (1) (2)	А	<u>(3)</u>	63,974	D	
Common Stock	02/25/201	9			А	7,500 (1) (4)	А	<u>(3)</u>	71,474	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Bolgiano Elizabeth Scott - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	TransactionDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 15.51	02/25/2019		А	20,000	(5)	02/25/2029	Common Stock	20,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Bolgiano Elizabeth Scott C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM, MA 02451			Chief Human Resources Officer				
Signatures							

/s/ Nancy R. Smith,	02/27/2019
attorney-in-fact	02/2//2015

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of the Issuer.

These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 (2) Equity Incentive Plan, as amended (the "Plan") that will vest in three equal annual installments with the first installment vesting on February 25, 2020.

(3) Not applicable.

These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance

(4) period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award.

Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) (5) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.

Edgar Filing: Bolgiano Elizabeth Scott - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.